CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The QuIC-ConCePT project aims to qualify imaging biomarkers for tumor cell processes to enhance drug development in cancer treatment. The goal is to ensure these biomarkers can be reliably used in clinical trials across multiple centers.
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials.
Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase I trials of investigational therapies, confident that the IBs are technically valid,…
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Sodertaelje
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
United Kingdom, Manchester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, MUENSTER
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
